Fiera Capital (Canada)
NBIX icon

Fiera Capital (Canada)’s Neurocrine Biosciences NBIX Stock Holding History

Fiera Capital (Canada)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.9M Sell
373,192
-278,063
-43% -$41.3M 0.23% 70
2026
Q1 		$85.8M Buy
651,255
+13,847
+2% +$1.84M 0.29% 62
2025
Q4 		$90.4M Buy
637,408
+157,732
+33% +$22.9M 0.29% 59
2025
Q3 		$67.3M Sell
479,676
-10,918
-2% -$1.48M 0.22% 68
2025
Q2 		$61.7M Sell
490,594
-3,881
-0.8% -$445K 0.21% 74
2025
Q1 		$54.7M Sell
494,475
-4,634
-0.9% -$587K 0.2% 71
2024
Q4 		$68.1M Sell
499,109
-17,692
-3% -$2.19M 0.21% 71
2024
Q3 		$59.5M Sell
516,801
-11,101
-2% -$1.52M 0.18% 78
2024
Q2 		$72.7M Buy
527,902
+16,360
+3% +$2.24M 0.23% 65
2024
Q1 		$70.6M Sell
511,542
-5,323
-1% -$727K 0.21% 71
2023
Q4 		$68.1M Buy
516,865
+5,497
+1% +$633K 0.21% 67
2023
Q3 		$57.5M Buy
511,368
+153,393
+43% +$16.2M 0.18% 67
2023
Q2 		$33.8M Sell
357,975
-11,392
-3% -$1.11M 0.1% 116
2023
Q1 		$37.4M Sell
369,367
-3,152
-0.8% -$328K 0.11% 104
2022
Q4 		$44.5M Sell
372,519
-2,568
-0.7% -$301K 0.14% 82
2022
Q3 		$37.5M Sell
375,087
-3,719
-1% -$377K 0.13% 85
2022
Q2 		$36.9M Sell
378,806
-4,880
-1% -$450K 0.11% 96
2022
Q1 		$36M Buy
383,686
+19,814
+5% +$1.68M 0.09% 126
2021
Q4 		$31M Sell
363,872
-38,600
-10% -$3.55M 0.07% 145
2021
Q3 		$38.6M Sell
402,472
-6,390
-2% -$604K 0.1% 111
2021
Q2 		$39.8M Sell
408,862
-9,348
-2% -$896K 0.1% 114
2021
Q1 		$40.7M Buy
418,210
+5,934
+1% +$622K 0.12% 113
2020
Q4 		$39.5M Buy
412,276
+126,651
+44% +$12.2M 0.11% 124
2020
Q3 		$27.5M Buy
+285,625
New +$33M 0.08% 142

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fiera Capital (Canada)'s NBIX Position: Q2 2026 in Review

Fiera Capital (Canada) reduced its Neurocrine Biosciences (NBIX) stake by 43% in Q2 2026, selling an estimated $41.3M and leaving 373,192 shares worth $62.9M. The position accounts for 0.23% of the portfolio, ranked #70.

Fiera Capital (Canada) first reported a position in NBIX in Q3 2020 and has held it in 24 quarters since. The position peaked at $90.4M in Q4 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Fiera Capital (Canada) held 373,192 shares of Neurocrine Biosciences worth $62.9M as of Q2 2026.
  • Fiera Capital (Canada) sold 278,063 Neurocrine Biosciences shares in Q2 2026, an estimated $41.3M.
  • Neurocrine Biosciences made up 0.23% of Fiera Capital (Canada)'s portfolio in Q2 2026, its #70 holding.
  • Fiera Capital (Canada) first reported a position in Neurocrine Biosciences in Q3 2020 and has held it in 24 quarters since.
  • Fiera Capital (Canada)'s Neurocrine Biosciences position peaked at $90.4M in Q4 2025.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Fiera Capital (Canada)'s 13F filing for Q2 2026, filed 7 Aug 2026.